Full metadata record

DC FieldValueLanguage
dc.contributor.author오창현-
dc.contributor.author모하메드 사미르-
dc.contributor.author마그디 아마르-
dc.date.accessioned2021-06-09T04:20:40Z-
dc.date.available2021-06-09T04:20:40Z-
dc.date.issued2018-10-
dc.identifier.citationVOL 158-166-
dc.identifier.issn0223-5234-
dc.identifier.other51370-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/68102-
dc.description.abstractFrequent oncogenic mutations have been identified in MAPK (mitogen-activated protein kinase) signaling pathway components. As a result, MAPK pathway is associated with human cancer initiation, in particular RAF (rapidly accelerated fibrosarcoma) component. The mutation in RAF component leads to auto-activation of MAPK signaling pathway, stimulating the uncontrolled cell growth and proliferation. In last few years, diverse chemical scaffolds have been identified as RAF inhibitors. Most of these scaffolds show potent anti-cancer activity. The present review highlights the recent investigations of RAF inhibitors during the last five years.-
dc.publisherEuropean journal of medicinal chemistry-
dc.subjectMAPK-
dc.subjectRAF 억제제-
dc.subjectAnti-Cancer agents-
dc.titleRecent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents-
dc.typeOther-
dc.relation.page144166-
Appears in Collections:
KIST Publication > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE